y90 edotreotide
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1998 (NCT00006368)
Timeline
Indications
Mechanism of action
- Somatostatin receptor 2INHIBITOR
SSTR2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 edotreotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00006370 | Phase 2 | Jul 1, 2000 | Novartis, University of South Florida |
| NCT00006368 | Phase 1 | Jan 1, 1998 | Novartis, University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 2 | 1998 |
| University of South Florida | Academic/Hospital | 2 | 0 | 2 | 1998 |
2 organizations
Page 1 / 1